Penumbra spikes after Stryker- Inari deal
140.52BUSD
Type
Common Stock
Exchange
NYSE
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US8636671013
CUSIP
863667101
Sector
Healthcare
Industry
Medical Devices
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
40.92
PEG Ratio
2.57
Book Value
52.86
Dividend Share
3.2
Dividend Yield
0.91%
Earnings Share
9.33
Wall Street Target Price
408.49
EPS Estimate Current Year
12.0566
EPS Estimate Next Year
13.4656
EPS Estimate Current Quarter
2.77
EPS Estimate Next Quarter
3.92
Most Recent Quarter
-
Revenue TTM
21,973,999,616
Gross Profit TTM
14,056,999,936
EBITDA
5,693,000,192
Profit Margin
16.34%
Return On Assets TTM
7.11%
Return On Equity TTM
18.87%
Revenue Per Share TTM
57.728
Qtly Revenue Growth YOY
11.90%
Diluted Eps TTM
9.33
Qtly Earnings Growth YOY
20.00%
Trailing PE
40.92
Forward PE
27
Price Sales TTM
6.6235
Price Book MRQ
6.974
Enterprise Value Revenue
6
Enterprise Value EBITDA
27
26.73
1.91%88.30
1.28%109.56
0.57%98.70
0.53%25.80
0.25%25.64
0.00%84.24
-0.67%113.49
-0.35%51.65
-0.18%69.78
-0.11%Penumbra spikes after Stryker- Inari deal
Stryker confirms deal to purchase Inari Medical for $80 a share
Inari Medical soars on report of Stryker talks
Stryker to buy pain therapy developer Vertos Medical
Stryker to acquire care.ai to expand healthcare IT portfolio